ZOMEDICA PHARMACEUTICALS STATEMENT STATEMENT OF INCORPORATION STATEMENT REGARDING THE TRANSACTION OF ZOMedica Pharmaceutical Products to The New York Stock Exchange INCORPMENT TRANSACTION AS OF NOVEMBER 15, 2018 (INCLUDING INCOME FROM ASSETS TRANSACTION AND ASSETS PURCHASED ON AND BEFORE DECEMBER 31, 2018) The Company entered into a transaction to acquire a wholly owned subsidiary, Zomedicas Pharmaceuticals Holdings Inc., for a price of $1.1 billion.
The transaction was completed on November 15, 2017.
The terms of the transaction were subject to certain conditions, including the appointment of a new board of directors.
ZOMMEDIA PHARMACIES FINANCIAL STATEMENTS REPORTS REGARD TO THE TRANSACTIONS INVOLVING THE SAME TERM, WITH NO EXCEPTIONS.
FOR AVAILABILITY OF THE INFORMATION, PLEASE CONTACT THE SECURITIES AND EXCHANGE COMMISSION AT (800) 671-7300.
All statements other than statements of historical fact contained herein have been qualified by reference to the Company’s filings with the SEC.
THE COMPANY DOES NOT ACT AS AN EXECUTIVE OFFICER OR DIRECTOR OF THE COMPONENT.